Abiopharma

🔍 Gomide de Faria Mariano (Executive)

Company: VTEX (NYSE: VTEX)

Report Date: 2026-08-26

Detailed Transactions and Holdings:

• Acquired 17,187 shares of Class A Common Shares (Direct)
  Date: 2026-08-26 | Code: C | equity_swap_involved: false | shares_owned_after: 618,984.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 17,187 shares of Class A Common Shares (Direct)
  Date: 2026-08-26 | Code: C | equity_swap_involved: false | shares_owned_after: 636,171.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 12,392 shares of Class A Common Shares at $4.39 per share (Direct)
  Date: 2026-08-26 | Code: J | equity_swap_involved: false | shares_owned_after: 623,779.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Class A Common Shares (Direct)
  Date: 2026-08-26 | Code: H | nature_of_ownership: By Class M | shares_owned_after: 14,100.00
• Holds 0 shares of Class A Common Shares (Direct)
  Date: 2026-08-26 | Code: H | nature_of_ownership: By Mira Limited | shares_owned_after: 913,929.00
• Sold 17,187 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-26 | Code: C | equity_swap_involved: false | shares_owned_after: 85,938.00 | transaction_form_type: 4 | Footnotes: F1, F3, F3
• Sold 17,187 shares of Restricted Stock Unit (Derivative)
  Date: 2026-08-26 | Code: C | equity_swap_involved: false | shares_owned_after: 154,688.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4

Footnotes:

• F1: Each Restricted Stock Unit ("RSUs") represents a contingent right to receive shares of Issuer Class A common stock on a one-for-one basis.
• F2: Reflects shares of Class A common stock withheld to cover tax withholding obligations in connection with the vesting restricted stock units reported herein
• F3: Represents RSUs, 25% of which vested on November 1, 2024, and the remaining amount of which vests in tranches of 6.25% every three (3) months thereafter
• F4: Represents RSUs, 25% of which vested on November 1, 2025, and the remaining amount of which vests in tranches of 6.25% every three (3) months thereafter.
• REMARKS: Due to the Issuer's status as a foreign private issuer pursuant to Rule 3a12-3(b) under the Securities Exchange Act of 1934 (the "Act"), the reporting person's transactions in the Issuer's equity securities are exempt from Sections 16(b) and 16(c) of the Act.